Does the media prefer PRGO or SUPN?

In the previous week, Perrigo had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 14 mentions for Perrigo and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.71 beat Perrigo's score of 0.01 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRGO or NKTR?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 15 mentions for Nektar Therapeutics and 14 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.02 beat Perrigo's score of 0.01 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PCRX or PRGO?

In the previous week, Perrigo had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 14 mentions for Perrigo and 11 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.64 beat Perrigo's score of 0.01 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media prefer OMER or PRGO?

In the previous week, Perrigo had 7 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Perrigo and 7 mentions for Omeros. Omeros' average media sentiment score of 0.32 beat Perrigo's score of 0.01 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRGO or ASMB?

In the previous week, Perrigo had 9 more articles in the media than Assembly Biosciences. MarketBeat recorded 14 mentions for Perrigo and 5 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.27 beat Perrigo's score of 0.01 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Perrigo (PRGO) Competitors

$10.34 -0.12 (-1.15%)

As of 12:46 PM Eastern

Compare

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

Should you buy Perrigo stock or one of its competitors? MarketBeat compares Perrigo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Perrigo include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Supernus Pharmaceuticals?

Perrigo (NYSE:PRGO) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Supernus Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A

Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 87.34%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 39.95%. Given Perrigo's higher probable upside, equities research analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

In the previous week, Perrigo had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 14 mentions for Perrigo and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.71 beat Perrigo's score of 0.01 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.9% of Perrigo shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Perrigo on 11 of the 16 factors compared between the two stocks.

How does Perrigo compare to Nektar Therapeutics?

Perrigo (NYSE:PRGO) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Perrigo presently has a consensus price target of $19.33, suggesting a potential upside of 87.34%. Nektar Therapeutics has a consensus price target of $149.63, suggesting a potential upside of 151.34%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Perrigo has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Nektar Therapeutics has lower revenue, but higher earnings than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A
Nektar Therapeutics	$55.63M	36.15	-$164.08M	-$8.42	N/A

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Nektar Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 15 mentions for Nektar Therapeutics and 14 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.02 beat Perrigo's score of 0.01 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nektar Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

How does Perrigo compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.22	$7.03M	$0.12	187.50
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Perrigo	-43.50%	9.96%	3.90%

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 0.4% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pacira BioSciences has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Perrigo had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 14 mentions for Perrigo and 11 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.64 beat Perrigo's score of 0.01 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacira BioSciences presently has a consensus price target of $29.40, indicating a potential upside of 30.67%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 87.34%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Pacira BioSciences beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Omeros?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

Omeros presently has a consensus target price of $40.33, suggesting a potential upside of 297.37%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 87.34%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Perrigo had 7 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Perrigo and 7 mentions for Omeros. Omeros' average media sentiment score of 0.32 beat Perrigo's score of 0.01 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.50
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A

48.8% of Omeros shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 12.9% of Omeros shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Omeros beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Assembly Biosciences?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Perrigo has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

In the previous week, Perrigo had 9 more articles in the media than Assembly Biosciences. MarketBeat recorded 14 mentions for Perrigo and 5 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.27 beat Perrigo's score of 0.01 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A
Assembly Biosciences	$71.10M	5.45	-$6.12M	-$0.11	N/A

Perrigo presently has a consensus price target of $19.33, suggesting a potential upside of 87.34%. Assembly Biosciences has a consensus price target of $42.75, suggesting a potential upside of 75.42%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Assembly Biosciences beats Perrigo on 9 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.43B	$7.91B	$6.26B	$23.13B
Dividend Yield	10.78%	2.56%	2.69%	4.09%
P/E Ratio	-0.79	15.37	22.35	31.16
Price / Sales	0.34	5.68	555.60	14.72
Price / Cash	2.03	17.23	42.31	24.78
Price / Book	0.48	3.52	9.82	4.68
Net Income	-$1.43B	$224.05M	$3.56B	$1.07B
7 Day Performance	-7.54%	-1.44%	-1.16%	-0.38%
1 Month Performance	-13.42%	-0.06%	3.85%	0.52%
1 Year Performance	-61.07%	-0.13%	27.33%	25.86%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	3.8215 of 5 stars	$10.34 -1.1%	$19.33 +87.0%	-60.9%	$1.43B	$4.25B	N/A	8,100
SUPN Supernus Pharmaceuticals	3.2494 of 5 stars	$48.21 flat	$62.17 +28.9%	+38.1%	$2.80B	$718.95M	N/A	580	Gap Up
NKTR Nektar Therapeutics	2.6143 of 5 stars	$66.61 flat	$149.63 +124.6%	+390.2%	$2.25B	$55.23M	N/A	220	Analyst Revision
PCRX Pacira BioSciences	3.9114 of 5 stars	$23.35 flat	$29.40 +25.9%	-15.2%	$918.78M	$726.41M	194.60	720
OMER Omeros	3.1348 of 5 stars	$11.46 flat	$40.33 +251.9%	+233.1%	$829.42M	N/A	16.37	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Summary

How does Perrigo compare to Nektar Therapeutics?

Summary

How does Perrigo compare to Pacira BioSciences?

Summary

How does Perrigo compare to Omeros?

Summary

How does Perrigo compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Perrigo (PRGO) Competitors

PRGO vs. SUPN, NKTR, PCRX, OMER, and ASMB

How does Perrigo compare to Supernus Pharmaceuticals?

Which has stronger earnings & valuation, PRGO or SUPN?

Which has more volatility & risk, PRGO or SUPN?

Do analysts rate PRGO or SUPN?

Is PRGO or SUPN more profitable?

Does the media prefer PRGO or SUPN?

Do institutionals & insiders hold more shares of PRGO or SUPN?

Summary

How does Perrigo compare to Nektar Therapeutics?

Do analysts rate PRGO or NKTR?

Which has more volatility and risk, PRGO or NKTR?

Which has stronger earnings & valuation, PRGO or NKTR?

Is PRGO or NKTR more profitable?

Do institutionals and insiders hold more shares of PRGO or NKTR?

Does the media favor PRGO or NKTR?

Summary

How does Perrigo compare to Pacira BioSciences?

Which has stronger earnings and valuation, PCRX or PRGO?

Is PCRX or PRGO more profitable?

Do insiders & institutionals believe in PCRX or PRGO?

Which has more volatility and risk, PCRX or PRGO?

Does the media favor PCRX or PRGO?

Do analysts recommend PCRX or PRGO?

Summary

How does Perrigo compare to Omeros?

Is OMER or PRGO more profitable?

Do analysts prefer OMER or PRGO?

Does the media prefer OMER or PRGO?

Which has more risk & volatility, OMER or PRGO?

Which has stronger earnings and valuation, OMER or PRGO?

Do insiders and institutionals hold more shares of OMER or PRGO?

Summary

How does Perrigo compare to Assembly Biosciences?

Is PRGO or ASMB more profitable?

Which has more risk & volatility, PRGO or ASMB?

Does the media refer more to PRGO or ASMB?

Do institutionals & insiders hold more shares of PRGO or ASMB?

Which has stronger valuation & earnings, PRGO or ASMB?

Do analysts rate PRGO or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools